Several analysts have recently updated their ratings and price targets for Valeant Pharmaceuticals Intl (NYSE: VRX):

  • 1/4/2018 – Valeant Pharmaceuticals Intl had its “sell” rating reaffirmed by analysts at Wells Fargo & Co.
  • 1/1/2018 – Valeant Pharmaceuticals Intl was given a new $25.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 12/26/2017 – Valeant Pharmaceuticals Intl was given a new $25.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 12/15/2017 – Valeant Pharmaceuticals Intl had its price target raised by analysts at Mizuho from $7.00 to $10.00. They now have an “underperform” rating on the stock.
  • 12/14/2017 – Valeant Pharmaceuticals Intl was downgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “underweight” rating. They now have a $12.00 price target on the stock.
  • 12/12/2017 – Valeant Pharmaceuticals Intl was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 12/5/2017 – Valeant Pharmaceuticals Intl was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $19.72 price target on the stock.
  • 12/4/2017 – Valeant Pharmaceuticals Intl was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $19.18 price target on the stock.
  • 12/3/2017 – Valeant Pharmaceuticals Intl was given a new $18.00 price target on by analysts at Deutsche Bank AG. They now have a “hold” rating on the stock.
  • 11/16/2017 – Valeant Pharmaceuticals Intl was given a new $18.00 price target on by analysts at Deutsche Bank AG. They now have a “hold” rating on the stock.
  • 11/13/2017 – Valeant Pharmaceuticals Intl had its “sell” rating reaffirmed by analysts at Wells Fargo & Co.
  • 11/13/2017 – Valeant Pharmaceuticals Intl had its price target raised by analysts at BMO Capital Markets from $16.00 to $17.00. They now have a “market perform” rating on the stock.
  • 11/10/2017 – Valeant Pharmaceuticals Intl had its “sell” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $12.00 price target on the stock.
  • 11/9/2017 – Valeant Pharmaceuticals Intl had its “hold” rating reaffirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock.
  • 11/8/2017 – Valeant Pharmaceuticals Intl was given a new $18.00 price target on by analysts at Royal Bank of Canada. They now have a “sector perform” rating on the stock.
  • 11/8/2017 – Valeant Pharmaceuticals Intl had its “hold” rating reaffirmed by analysts at Deutsche Bank AG. They now have a $19.00 price target on the stock.
  • 11/7/2017 – Valeant Pharmaceuticals Intl was upgraded by analysts at TheStreet from a “d” rating to a “c-” rating.
  • 11/7/2017 – Valeant Pharmaceuticals Intl was upgraded by analysts at TD Securities from a “hold” rating to a “buy” rating. They now have a $20.00 price target on the stock.

Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) opened at $23.05 on Friday. The company has a market cap of $8,021.10, a price-to-earnings ratio of 5.91, a price-to-earnings-growth ratio of 0.68 and a beta of -0.22. Valeant Pharmaceuticals Intl Inc has a 1 year low of $8.31 and a 1 year high of $23.47. The company has a debt-to-equity ratio of 4.84, a quick ratio of 1.03 and a current ratio of 1.26.

In other Valeant Pharmaceuticals Intl news, Director John Paulson acquired 344,216 shares of the firm’s stock in a transaction that occurred on Thursday, November 16th. The shares were acquired at an average cost of $14.40 per share, for a total transaction of $4,956,710.40. Following the transaction, the director now directly owns 94,559 shares of the company’s stock, valued at $1,361,649.60. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 5.87% of the stock is owned by insiders.

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with MarketBeat.com's FREE daily email newsletter.